TAIPEI, Sept. 16, 2024 /PRNewswire/ -- The Asian Safety & Security Online Exhibition 2024 (ASSOE 2024) is a hybrid event that integrates virtual and physical elements, targeting Asian suppliers, importers, and exporters. The exhibition will run from September 16, 2024, to December 31, 2024, offering an excellent opportunity for exhibitors to showcase their brands. This transnational trade event, jointly organized by AsianNet and TradeAsia (www.e-tradeasia.com), has been held since 2022, yielding satisfactory results in both quality and quantity. In 2024, we will expand the scale of the event. The four-month extension period will align with the schedules of the NSC Safety Congress & Expo, SECURITY ESSEN, and FISP 2024 International Fair of Safety and Protection, creating collective momentum. This alignment will make it convenient for international buyers to visit and compare options in a single purchasing experience.
TradeAsia, the organizer of ASSOE 2024, has extended invitations to dozens of leading Taiwanese suppliers in the safety and security sector. Esteemed brands including A-BELT-LIN INDUSTRIAL, PAN TAIWAN ENTERPRISE, DORIS INDUSTRIAL, MODERN AUTO, JI JUSTNESS INDUSTRIAL, CLEVER INTELLIGENCE UNITY, ABA LOCKS INTERNATIONAL, PERFECT MEDICAL INDUSTRY, LITEFILM TECH, ET&T TECHNOLOGY, FORMOSA GLOVE INDUSTRIAL, YAU YOUNG AUTO PARTS and HARCO ENTERPRISE are set to exhibit their latest innovations.
Capitalizing on its strong partnerships with industry leaders, ASSOE 2024 will showcase an extensive selection of cutting-edge safety and security products. The exhibition will highlight diverse product categories such as access control system & products, alarm & sensor, CCTV products, auto safety & security products, firefighting & protection, lock & safe, personal protection & self-defense, police & military supply, roadway safety supply, security service, water safety products, workplace safety products, building apparatus, smart electronics, camera & camera accessories. With thousands of the latest products, accessories, and solutions on display, the exhibition promises a rich and highly professional experience for all attendees.
ASSOE 2024 Online Exhibition：
https://www.etradeasia.com/online-show/35/Asian-Safety-Security-Online-Exhibition-2024.html
In response to the continued impact of COVID-19 on international travel, ASSOE 2024 offers a suite of online exhibition solutions designed to bridge gaps and expand market reach. These solutions include dedicated exhibitor pages, electronic catalogs, and virtual exhibition halls, all seamlessly integrated with TradeAsia. This allows international buyers—regardless of geographic distance—to easily explore products and connect with exhibitors in real time. Buyers can visit specific manufacturer pages, leave inquiries, and initiate procurement discussions without the constraints of travel.
Since its founding in 1997, TradeAsia (www.e-tradeasia.com) has been a leading B2B international trade platform, facilitating connections between buyers and sellers across the globe. With millions of global members, over 600,000 suppliers, and a vast catalog of products, TradeAsia has become a key trade promotion channel in Asia. Thousands of professional buyers rely on the platform daily to discover new products and establish business partnerships.
TradeAsia collaborates with hundreds of trading entities worldwide, facilitating marketing and promotional exposure across various platforms. Suppliers featured on TradeAsia benefit from increased visibility through these global partnerships, enhancing their international marketing reach. Additionally, ASSOE 2024 will broadcast promotional messages worldwide, further amplifying your exposure during this period.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Asian Safety & Security Online Exhibition 2024 Grand Opening
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals.
Biosyngen, an innovative biotechnology company specializing in immune cell therapies, is proud to present Phase I clinical data for its pioneering CAR-T therapy targeting Epstein-Barr virus (EBV) antigens for the treatment of nasopharyngeal carcinoma (NPC).
Abstract Title
Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer (NPC) patients
Abstract No.:
899P
The presentation highlights that the Phase I clinical trial of BRG01 has successfully completed dose-limiting toxicity (DLT) observations and efficacy evaluations in nine patients, all diagnosed with advanced NPC. Notably, 100% of participants had previously undergone platinum-based chemotherapy and failed at least one immune checkpoint inhibitor, including PD-1 antibodies, while 45% had also failed treatment with antibody-drug conjugates (ADCs).
Preliminary data indicates that BRG01 demonstrates exceptional safety and preliminary efficacy. In terms of safety, no cases of dose-limiting toxicity, neurotoxicity, grade 2 or higher cytokine release syndrome, or treatment-related death were observed. The most common grade 3 adverse events were transient leukopenia related to the lymphodepletion regimen.
In terms of efficacy, disease control and response rates exhibited a clear dose-dependent relationship. Higher doses led to more significant effects, with 75% of patients experiencing a sustained reduction in tumor burden and diminished metabolic activity, and several lesions achieving complete response (CR) with 100% tumor reduction.
Patients treated with BRG01 have shown a progression-free survival exceeding six months post-infusion, demonstrating significantly extended antitumor effects compared to the current standard treatment, checkpoint inhibitors like PD-1 antibodies.
Additionally, BRG01 exhibited remarkable antiviral efficacy, with a significant reduction in EBV viral load in peripheral blood to normal levels post-infusion.
Professor Zhang Li, the principal investigator (PI) of this clinical trial, and Director of the Phase I Unit at Sun Yat-sen University Cancer Center, stated, "BRG01 has the potential to be a 'first-in-class' T cell therapy for EBV-positive tumors. Its unique mechanism and robust Phase I data instill confidence in its Phase II clinical performance. We look forward to establishing its clinical efficacy through further studies, offering new hope for more patients."
As previously reported, BRG01 has received regulatory approvals for Phase II clinical trials in July (China) and August (U.S.) with patient enrollment now underway.
These data not only underscore the potential of BRG01 in treating cancer but also highlights its dual advantages in antiviral therapy, establishing a solid foundation for future clinical applications. This is likely a key factor in the Center for Drug Evaluation, NMPA and FDA's decision to advance BRG01 to Phase II trials.
BRG01 is an autologous T cell immunotherapy that expresses a chimeric receptor targeting EBV antigens through genetic modification. It represents Biosyngen's global innovation in next-generation CAR-T cell therapy specifically for EBV. The therapy received clinical trial approval from the CDE in December 2022 and the FDA in February 2023. Subsequently, it was granted orphan drug designation (ODD) and fast track designation (FTD) by the FDA in June and July 2023, respectively, marking rapid simultaneous progress in both the U.S. and China.
Biosyngen's commitment to solid tumor cell therapies extends beyond BRG01. The company is emerging as a biotech leader with a portfolio that includes CAR-T, TCR-T, and TIL therapies targeting both solid and hematologic tumors. All related product pipelines have achieved simultaneous regulatory submissions and approvals in both the U.S. and China, covering various solid tumors, including lung and liver cancer.
Regarding the initial release of BRG01's Phase I clinical data, Dr. Michelle Chen, co-founder and CEO of Biosyngen, stated, "BRG01 is the result of years of hard work by our team and a testament to the recognition of our core technology and research capabilities. Biosyngen is committed to developing innovative drugs that address unmet clinical needs in oncology. In the future, we will continue to increase our R&D investments and expedite the clinical trial and commercialization processes for BRG01, providing more effective and accessible treatment options for patients worldwide."
With Biosyngen's efficient execution and rapid research advancements, we have reason to be optimistic about achieving further clinical breakthroughs in solid tumor cell therapies in a shorter timeframe, bringing new hope to patients.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
